Leukaemic cells in patients with type A NPM1 mutation strongly expressed myeloperoxidase (MPO) and CD33 with dim expression of other myelomonocytic antigens commonly expressed in AML including CD13, CD65, CD15, and CD14. This evidence concerns the gene MPO and acute myeloid leukemia.